Yep, efficacy will definitely bring world-wide attention to this humble little stock that right now is quietly hidden away in the world's most remote city, and with it a MC that will be many, many multiples of where it sits currently.
Triple this you say Zac? I would suggest waaay beyond triple if efficacy is shown myself.
As the board of AGN put it, Proving the neuroprotective ability of ARG-007 will be a significant derisking milestone for the Company and opportunity to place Argenica at the forefront of neuroprotective clinical validation.
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007, page-16
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
77.0¢ |
Change
-0.115(13.0%) |
Mkt cap ! $95.24M | |||
| Open | High | Low | Value | Volume |
| 87.0¢ | 87.0¢ | 77.0¢ | $295.6K | 363.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 25209 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 83.0¢ | 19703 | 1 |
View Market Depth
| Last trade - 15.57pm 05/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |